PURPOSE: We have shown previously that exposure to anticancer drugs can trigger the activation of human epidermal receptor survival pathways in colorectal cancer (CRC). In this study, we examined the role of ADAMs (a disintegrin and metalloproteinases) and soluble growth factors in this acute drug resistance mechanism. EXPERIMENTAL DESIGN: In vitro and in vivo models of CRC were assessed. ADAM-17 activity was measured using a fluorometric assay. Ligand shedding was assessed by ELISA or Western blotting. Apoptosis was assessed by flow cytometry and Western blotting. RESULTS: Chemotherapy (5-fluorouracil) treatment resulted in acute increases in transforming growth factor-alpha, amphiregulin, and heregulin ligand shedding in vitro and in vivo that correlated with significantly increased ADAM-17 activity. Small interfering RNA-mediated silencing and pharmacologic inhibition confirmed that ADAM-17 was the principal ADAM involved in this prosurvival response. Furthermore, overexpression of ADAM-17 significantly decreased the effect of chemotherapy on tumor growth and apoptosis. Mechanistically, we found that ADAM-17 not only regulated phosphorylation of human epidermal receptors but also increased the activity of a number of other growth factor receptors, such as insulin-like growth factor-I receptor and vascular endothelial growth factor receptor. CONCLUSIONS: Chemotherapy acutely activates ADAM-17, which results in growth factor shedding, growth factor receptor activation, and drug resistance in CRC tumors. Thus, pharmacologic inhibition of ADAM-17 in conjunction with chemotherapy may have therapeutic potential for the treatment of CRC.
PURPOSE: We have shown previously that exposure to anticancer drugs can trigger the activation of human epidermal receptor survival pathways in colorectal cancer (CRC). In this study, we examined the role of ADAMs (a disintegrin and metalloproteinases) and soluble growth factors in this acute drug resistance mechanism. EXPERIMENTAL DESIGN: In vitro and in vivo models of CRC were assessed. ADAM-17 activity was measured using a fluorometric assay. Ligand shedding was assessed by ELISA or Western blotting. Apoptosis was assessed by flow cytometry and Western blotting. RESULTS: Chemotherapy (5-fluorouracil) treatment resulted in acute increases in transforming growth factor-alpha, amphiregulin, and heregulin ligand shedding in vitro and in vivo that correlated with significantly increased ADAM-17 activity. Small interfering RNA-mediated silencing and pharmacologic inhibition confirmed that ADAM-17 was the principal ADAM involved in this prosurvival response. Furthermore, overexpression of ADAM-17 significantly decreased the effect of chemotherapy on tumor growth and apoptosis. Mechanistically, we found that ADAM-17 not only regulated phosphorylation of human epidermal receptors but also increased the activity of a number of other growth factor receptors, such as insulin-like growth factor-I receptor and vascular endothelial growth factor receptor. CONCLUSIONS: Chemotherapy acutely activates ADAM-17, which results in growth factor shedding, growth factor receptor activation, and drug resistance in CRC tumors. Thus, pharmacologic inhibition of ADAM-17 in conjunction with chemotherapy may have therapeutic potential for the treatment of CRC.
Authors: Susan Wohler Sunnarborg; C Leann Hinkle; Mary Stevenson; William E Russell; Christina S Raska; Jacques J Peschon; Beverly J Castner; Mary J Gerhart; Raymond J Paxton; Roy A Black; David C Lee Journal: J Biol Chem Date: 2002-01-31 Impact factor: 5.157
Authors: Christian Hundhausen; Dominika Misztela; Theo A Berkhout; Neil Broadway; Paul Saftig; Karina Reiss; Dieter Hartmann; Falk Fahrenholz; Rolf Postina; Vance Matthews; Karl-Josef Kallen; Stefan Rose-John; Andreas Ludwig Journal: Blood Date: 2003-04-24 Impact factor: 22.113
Authors: Wendy L Allen; Richard C Turkington; Leanne Stevenson; Gail Carson; Vicky M Coyle; Suzanne Hector; Philip Dunne; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston Journal: Mol Cancer Ther Date: 2012-06-04 Impact factor: 6.261
Authors: Sandra Van Schaeybroeck; Wendy L Allen; Richard C Turkington; Patrick G Johnston Journal: Nat Rev Clin Oncol Date: 2011-02-15 Impact factor: 66.675
Authors: Robbie Carson; Basak Celtikci; Patrick G Johnston; Sandra Van Schaeybroeck; Cathy Fenning; Arman Javadi; Nyree Crawford; Lucia Perez Carbonell; Mark Lawler; Daniel B Longley Journal: Clin Cancer Res Date: 2015-03-26 Impact factor: 12.531
Authors: Ranee Mehra; Ilya G Serebriiskii; Roland L Dunbrack; Matthew K Robinson; Barbara Burtness; Erica A Golemis Journal: Drug Resist Updat Date: 2011-09-14 Impact factor: 18.500
Authors: Sandra Van Schaeybroeck; Joan N Kyula; Audrey Fenton; Catherine S Fenning; Takehiko Sasazuki; Senji Shirasawa; Daniel B Longley; Patrick G Johnston Journal: Cancer Res Date: 2010-12-10 Impact factor: 12.701
Authors: Philip D Dunne; Sonali Dasgupta; Patrick G Johnston; Sandra Van Schaeybroeck; Jaine K Blayney; Darragh G McArt; Keara L Redmond; Jessica-Anne Weir; Conor A Bradley; Takehiko Sasazuki; Senji Shirasawa; Tingting Wang; Supriya Srivastava; Chee Wee Ong; Ken Arthur; Manuel Salto-Tellez; Richard H Wilson Journal: Clin Cancer Res Date: 2015-08-17 Impact factor: 12.531